Noopept capsules, the chemical name is N-phenylacetyl-L-prolyl glycine ethyl ester, which is a cyclic glycine proline dipeptide derivative developed in Russia. This substance significantly enhances its bioavailability and blood-brain barrier penetration ability through modification with phenylacetyl and ethyl ester functional groups. Animal experiments have shown that the peak concentration (1.289 μ g/mL) in brain tissue can be reached within 7 minutes after oral administration of 8mg/kg dose, and there is no significant difference in serum and nerve tissue concentrations, confirming its efficient transmembrane properties.
The capsule adopts microcrystalline cellulose carrier technology to ensure stable drug release in the gastrointestinal tract. The oral bioavailability reaches 89%, far exceeding the 1-2% of piracetam, thanks to the avoidance effect of its ethyl ester group on the first pass effect. The peak time of blood drug concentration (Tmax) is 0.115 hours (7 minutes), Cmax is 1.289 μ g/mL (8mg/kg dose), and the ratio of brain tissue concentration to serum concentration is 1:0.98, confirming its excellent blood-brain barrier penetration ability.
Our product
Additional information of chemical compound:
| Product Name | Noopept Powder | Noopept Tablets | Noopept Capsules |
| Product Type | Powder | Tablet | Capsules |
| Product Purity | ≥99% | ≥99% | ≥99% |
| Product Specifications | Customizable | Customizable | Customizable |
| Product Package | Customizable | Customizable | Customizable |
Our Product
Noopept +. COA
 |
||
Certificate of Analysis |
||
|
Compound name |
Noopept | |
|
CAS No. |
157115-85-0 | |
|
Grade |
Pharmaceutical grade | |
|
Quantity |
Customized | |
|
Packaging standard |
Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
|
Lot No. |
20250109001 |
|
|
MFG |
Jan 12th 2025 |
|
|
EXP |
Jan 8th 2029 |
|
|
Structure |
|
|
| TEST STANDARD | GB/T24768-2009 Industry. Stnndard | |
|
Item |
Enterprise standard |
Analysis result |
|
Appearance |
White or almost white powder |
Conformed |
|
Water content |
≤4.5% |
0.30% |
| Loss on drying |
≤1.0% |
0.15% |
|
Heavy Metals |
Pb≤0.5ppm |
N.D. |
|
As≤0.5ppm |
N.D. | |
|
Hg≤0.5ppm |
N.D. | |
|
Cd≤0.5ppm |
N.D. | |
|
Purity (HPLC) |
≥99.0% |
99.5% |
|
Single impurity |
<0.8% |
0.48% |
|
Residue on ignition |
<0.20% |
0.064% |
|
Total microbial count |
≤750cfu/g |
80 |
|
E. Coli |
≤2MPN/g |
N.D. |
|
Salmonella |
N.D. | N.D. |
|
Ethanol (by GC) |
≤5000ppm |
400ppm |
|
Storage |
Store in a sealed, dark and dry place at-20 degrees |
|
|
|
||
Pharmacokinetic characteristics
Absorption and distribution:
Noopept capsules is oral bioavailability reaches 89%, far exceeding Piracetam (1-2%). Sublingual administration can bypass the first pass effect, but caution should be taken against the risk of sudden blood pressure drop - animal experiments have shown that 0.5mg/kg sublingual administration can reduce mean arterial pressure by 22 ± 3mmHg for about 45 minutes.
Metabolism and excretion:
Mainly metabolized by liver CYP3A4 enzyme, producing L-isomer metabolites with anti anxiety activity. The half-life is 1.1-1.5 hours, and it needs to be administered in divided doses daily to maintain a steady state concentration.
Formulation difference:
There is a dispute over the bioequivalence between the Russian version of sublingual tablets (10mg) and the American version of capsules (30mg). According to a 2023 Zhihu user survey, 62% of users believe that sublingual tablets take effect faster (15-20 minutes vs. capsules 30-45 minutes), but the duration of action in the capsule group is extended to 6-8 hours.
Mild cognitive impairment (MCI): In a double-blind trial in 2025, 268 patients were enrolled. The experimental group (20mg/d) showed a 3.8 point improvement in MMSE scores (1.2 points in the placebo group) and a 4.1 point decrease in ADAS Cog scores (p<0.01). Especially in the execution function sub item, the completion time of Trail Making Test-B in the experimental group was reduced by 28%.
Vascular dementia: A 56 day intervention study showed that the 20mg/d group increased MoCA scores by 2.7 points, shortened the latency of event-related potential P300 by 32ms, indicating an improvement in information processing speed.
Traumatic brain injury: An open label trial of 17 patients with post-traumatic cognitive impairment showed that after continuous medication for 90 days, the total RBANS score increased by 19.3 points (p=0.003), with the visual spatial processing sub item showing the most significant improvement (+24.6 points).
Custom Notebook Solutions
Emerging application areas
Biohacking Practice: Entrepreneur Jeffrey Wu's self experiment report shows that after continuous use for 30 days, color saturation perception increased by 37% (verified by FM100 color vision test), and auditory detail recognition threshold decreased by 12dB (pure tone hearing test).
Neurodegenerative disease assistance: Alzheimer's disease model mice experiments have shown that combined treatment with memantine can delay hippocampal atrophy by 41% and reduce Tau protein phosphorylation levels by 29%.
Comorbidity Management of Mental Disorders: A randomized controlled trial (RCT) study of 53 patients with vascular depression showed that after 8 weeks of treatment with 20mg/d combined with SSRIs, the decrease in HAMD-17 score increased by 5.2 points compared to the monotherapy group (p=0.03), and there was no increased risk of QTc interval prolongation.
Noopept capsules is a synthetic intelligence promoting drug originating from Russia. Its capsule form enters the human body through oral administration and improves cognitive function through multi-target synergistic effects. Its mechanism of action involves four core pathways: neuroprotection, neurotransmitter regulation, growth factor stimulation, and antioxidant defense.
Noopept significantly enhances the survival and differentiation ability of neural stem cells through the IL-6 mediated overexpression mechanism of brain-derived neurotrophic factor (BDNF). Animal experiments have shown that after administration, the concentration of BDNF in the hippocampus increased by 2.1 times compared to the control group. This effect is directly related to the decrease in IL-6 concentration - a decrease in IL-6 levels in the brain can relieve the inhibition of BDNF gene expression and promote neuronal synaptic plasticity. For example, in a traumatic brain injury model, the Noopept treatment group increased the survival rate of hippocampal neurons by 37% and prolonged spatial memory retention time to 2.3 times that of the control group.
Its neuroprotective effect is also reflected in the regulation of calcium channels. As a calcium channel antagonist, Noopept can block glutamate induced overactivation of NMDA receptors and reduce neuronal apoptosis induced by calcium influx. Preclinical studies have confirmed that a dose of 0.5mg/kg can reduce the area of excitotoxic injury by 41%, and this mechanism is highly correlated with stroke protective effects.
Neurotransmitter system regulation: cholinergic and glutamatergic balance
Cholinergic system enhancement:
Noopept enhances learning and memory function by promoting acetylcholine release. Its targets include cholinergic neurons in the basal forebrain and M1 receptors in the hippocampus. Animal behavioral experiments have shown that after administration, the accuracy of new object recognition tasks in mice increased by 28%, and the effect was not related to acetylcholinesterase activity inhibition, indicating direct action on the presynaptic membrane release mechanism.
Glutamic acid system regulation:
Unlike traditional glutamate receptor agonists, Noopept adopts a "negative regulation" strategy: by competitively occupying the NMDA receptor glycine binding site, it reduces the probability of receptor opening, thereby reducing oxidative stress caused by calcium overload. Electrophysiological records show that a concentration of 10nM can reduce the amplitude of excitatory postsynaptic potential (EPSP) in hippocampal pyramidal cells by 34%, without affecting AMPA receptor-mediated basal conduction.
Noopept can simultaneously upregulate the expression of nerve growth factor (NGF) and BDNF, forming a neuroprotective double insurance. In the in vitro neurosphere culture experiment, after 72 hours of treatment with a concentration of 1 μ M:
NGF secretion increased by 2.7 times
BDNF mRNA expression upregulated by 4.1-fold
The growth rate of neural processes has increased by 58%
This synergistic effect was validated in a vascular dementia model: after continuous administration for 56 days, the patient's serum BDNF level increased from 18.3 ng/mL to 25.7 ng/mL, and the MMSE score improved by 3.8 points (placebo group 1.2 points). It is worth noting that its stimulating effect has a dose-dependent threshold - growth factor expression tends to saturate when it exceeds 30mg/d.
Antioxidant defense system: dynamic balance of SOD/MDA
Noopept constructs an antioxidant barrier by enhancing the activity of superoxide dismutase (SOD). The H ₂ O ₂ - induced neuronal damage model shows:
10nM concentration increases SOD activity by 2.3 times
The content of lipid peroxidation product MDA decreased by 67%
Cell survival rate increased from 58% to 89%
Its antioxidant mechanism is related to the activation of the nuclear factor E2 related factor 2 (Nrf2) pathway. Gene chip analysis showed that downstream genes of Nrf2 (such as HO-1 and GCLC) were upregulated 3-5 times after administration, forming a sustained antioxidant effect. This characteristic makes it perform well in the ischemia-reperfusion injury model - the cerebral infarction volume is reduced by 42%, and the neurological deficit score is reduced by 51%.
Usage standards and optimization strategies
Standardized treatment plan
Dose gradient:
Cognitive enhancement: 10-20mg/d, taken orally in two doses
Neuroprotection: 30mg/d, combined with vitamin E 400IU/d
Trauma recovery: 40mg/d (to be used under supervision)
Medication schedule: It is recommended to take 12 weeks as one course of treatment, and stop taking medication for 2 weeks between each course to prevent receptor desensitization. The long-term follow-up study in 2024 showed that the cognitive maintenance effect of the intermittent medication group (stopping for 2 weeks after 4 weeks) was better than that of the continuous medication group (p=0.04).
Efficiency enhancing combination plan
Cholinergic enhancement: When used in combination with 300mg/d alpha GPC, it can improve the accuracy of working memory tasks by 23% (compared to 14% in the monotherapy group).
Antioxidant synergy: Combined with 200mg/d coenzyme Q10, it can reduce serum MDA levels by 31% and increase SOD activity by 19%.
Neuroplasticity Promotion: When combined with Omega-3 fatty acids (EPA 1000mg+DHA 500mg), the body volume of seahorses increased by 2.1% after 6 months, significantly better than the monotherapy group (0.7%).
Market pattern and regulatory dynamics
Global Regulatory Classification
Russia: included as a prescription drug in medical insurance for cognitive rehabilitation after brain injury.
United States: Classified as an uncontrolled substance under the Federal Food, Drug, and Cosmetic Act, but not approved for medical use by the FDA, classified as a "gray area" product.
EU: Some countries (such as Poland and Bulgaria) allow the sale of dietary supplements, but they must be labeled with the warning "not evaluated by FDA".
Quality Control Standards
Purity requirements: USP standards require a minimum of 98.5%, heavy metal content ≤ 10ppm, and residual solvents (chloroform, ethanol) in accordance with ICH guidelines.
Stability test: Accelerated test (40 ℃/75% RH) showed that the content of tablets decreased by ≤ 2.3% and capsules decreased by ≤ 3.1% within 12 months.
Bioequivalence: The FDA requires the Cmax ratio of sublingual tablets to oral formulations to be within the range of 80-125%, and the AUC ratio to be within the range of 85-115%.
The clinical value of Noopept capsules as a new generation cognitive enhancer has been preliminarily validated, but long-term safety data still needs to be improved. In the era of precision medicine, establishing personalized medication plans based on biomarkers will be a key path to breaking through existing therapeutic bottlenecks. In the future, with the deepening of neuroscience mechanism research, this drug is expected to play a greater role in the prevention of neurodegenerative diseases.
Frequently Asked Questions
What is Noopept good for?
+
-
Noopept is a powerful nootropic compound known for its cognitive-enhancing properties. With its unique structure, it is recognized for promoting memory, learning, and overall mental clarity.
How does Noopept affect the brain?
+
-
By doing so, Noopept may promote synaptic plasticity, facilitating the formation of new connections between neurons and enhancing synaptic transmission. This property is believed to underlie its ability to improve learning, memory consolidation, and cognitive flexibility.
Does noopept make you sleepy?
+
-
Possible side effects of noopept included sleep disturbances (5/31 patients), irritability (3/31), and increased blood pressure (7/31) (Neznamov and Teleshova, 2009). Mechanisms of action from preclinical research One study in rodents reported that noopept crossed the blood brain barrier.
Does Noopept help with anxiety?
+
-
Noopept, however, produces a nootropic effect at much lower concentrations and can be applied over a wider range of pathological conditions; for example, it also displays anxiolytic effects and is used in anxiety treatment.
Hot Tags: noopept capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale